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Summary.-Serum testosterone (T) and dihydrotestosterone (DHT) were measured
by a sensitive and reliable radioimmunoassay in 42 normal subjects and 33 age-
matched patients with carcinoma of the prostate. The mean +s.e. for serum testo-
steronein normal subjects was 16-74h076nM andthecorresponding value forpatients
with carcinoma was 20-94±1-48nM. Statistical analysis of the results showed a sig-
nificant increase in T level in patients with carcinoma of the prostate (P<001). In
contrast, there was no difference in DHT concentration between the two groups,
values being2-43±0-09 and206±009nM for normal subjects andpatientsrespectively.
The means +s.e. for T/DHT ratio in controls and patients were 68+O0-2 and 12-8±1*3
respectively. The difference was highly significant (P<0001). The wide range of
variation for T in patients with carcinoma would suggest that although mean T
is higher in these patients, this measurement alone is oflittle practical value, whereas
T/DHT ratio is a more reliable parameter in evaluating the androgen changes in these
patients. The significance of these findings in relation to the aetiology of the disease
is discussed.
PROSTATIC NEOPLASIA and hyperplasia are
both diseases of advancing age, and pre-
sent at a time of life when testicular func-
tion is in decline. In normal men the asso-
ciation between ageing and declining
plasma androgen levels is now becoming
clearer (Editorial, Brit. med. J., 1975;
Lewis et at., 1976). However, the growth
and continued function of both benign
hyperplasia and carcinoma are dependent
on the continued availability ofandrogens
(Huggins & Hodges, 1941; Ghanadian
et al., 1975a). Hence the develop-
ment of these conditions at this particu-
lar time appears to be something of a
paradox.
Data on androgen levels in carcinoma of
the prostate are sparse and at times con-
flicting; rather more information has re-
cently become available from studies in
patients with benign hyperplasia. High
tissue levels ofdihydrotestosterone (DHT)
have been reported in benign hyperplasia
(Siiteri & Wilson, 1970) and circulating
plasma levels of this steroid have been
found to be higher in patients with BPH
than in normal subjects (Horton et al.,
1975; Vermeulen & Desy, 1976; Ghanadian
et al., 1977). However, this latter finding
has not been detected by some investi-
gators (Harper et al., 1976). Studies on
androgen levels in prostatic tissue indicate
that the concentration of testosterone (T)
is significantly higher in carcinoma than
in BPH (Habib et al., 1976). The present
study was designed to investigate changes
in plasma T and DHT in patients with
carcinoma of the prostate and age-
matched controls, to relate these findings
to the clinical picture and to evaluate the
possible implications to the aetiology of
this disease.
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MATERIALS AND METHODS
Thirty-three patients with histologically
proven carcinoma ofthe prostate, aged 56-85
years, and 42 normal men aged 50-81 years
were used in this study. The mean ages ±s.e.
for these two groups were 6941 and 61+1
respectively. The patients had received no
treatment for their disease. The normal sub-
jects were all in good health and free from
urological and endocrinological symptoms.
They were chosen from a screening unit
where they had attended for a routine
medical examination.
Venous blood was drawn between 10.00 and
12.00 hours. Serum was separated within
30 min of collection and stored at -20°C
before assay.
Testosterone and 5 cy-dihydrotestosterone
were measured by a sensitive and reliable
radioimmunoassay technique developed inour
laboratory (Ghanadian et al., 1975b). Anti-
body was generated in New Zealand white
rabbit against testosterone 3-oxime coupled
to bovine serum albumin, and the specificity
of this antiserum was extensively studied.
The within-assay variation on human pool
serum gave a coefficient ofvariation of 11-6%
for T and 6.5% for DHT. The between-assay
variation was found to be 9.2% and 6 5% for
T and DHT respectively. The sensitivity of
this technique for T was 17-4pM and for
dihydrotestosterone 344pM. The two steroids
were separated by thin-layer chromatography
and subsequently assayed.
RESULTS
Serum T and DHT were measured in 42
normal subjects and 33 patients with
carcinoma of the prostate. The results are
TABLE. Serum testosterone (T) and di-
hydrotestosterone (DHT) in 42 normal
subjects and 33 patients with carcinoma
of the prostate (mean±s.e. and range for
each steroid are shown)
T
(IIM)
DHT
(nm)
T/DHT
Normal
subjects
(50-81 yeats)
16-74±0-76
(8-95-34-21)
2-43±0 09
(1*44-4-16)
6-8±0-2
(3-7-10-3)
Ca prostate
(56-85 years)
20-94± 1-48
(5.0-37.0)
2 06±0-09
(0)05-5 2)
12-8+ 1-3 (3.6-33:3)
shown in the Table. There were wide
variations in the level of T and DHT in
both groups. However, statistical analysis
of the results revealed a significantly
higher level of T in patients with car-
cinoma of the prostate than in the normal
group (P<0 01; Table). Such a difference
could not be found for DHT. There was
good correlation between T and DHT in
normal subjects, r 0-72 (P<0001; Fig.
1). A similar relationship, though less
significant, was found in patients with
carcinoma of the prostate, r=0-36
(P<0 05; Fig. 2).
The ratio was found to be significantly
different (P<0*001) between normal men
and patients with carcinoma of the
prostate; values being 6-8±0-2 and 12-8S
1-3 (mean±s.e.) respectively.
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reported to increase with age in normal
men (Pirk & Doerr, 1973). Changes in
C C * SHBG will influence the ratio between
free and bound T. However, there has
* * been no significant difference between the
SHBG in patients with carcinoma of the
prostate and the age-matched normal
groups. Dennis et al. (1977) and Bartsch
et al. (1977a) compared SHBG-binding
capacity ofpatients with carcinoma ofthe
prostate aged 50-85 years and age-
matched normal men. They found the
values for patients varied between 3 40
and 4-70 x 108M and the corresponding
* value for normal men was 3*07-4-27
X 108M. Statistical analysis of their find-
ings revealed no significant difference
between the two groups. This would sug-
gest that the observed increase in the level
* * y = 2.62x + 15.55 of T in patients with carcinoma of the
r < 0.05 prostate in our investigation is inde-
n= 33 pendent of SHBG.
There have been several studies com-
paring circulating androgens in normal
men and patients with carcinoma of the
prostate. Some, however, have lacked a
sensitive method of measurement, others
1 2 3 4 5 an adequate population for proper assess-
Serum dihydrotestosterone ( nM) ment or an age-matched control group.
-Correlation between serum testo- Robinson & Thomas (1971) measured
ne and dihydrotestosterone in patients serum T by gas-liquid chromatography in
carcinoma of the prostate. 25 normal men with an age range of 20 to
DISCUSSION 78 years and in 45 patients with carcinoma with an age range of 50 to 81 years and
esults clearly demonstrate that the found no significant difference. Two other
T in patients with carcinoma ofthe groups (Harper et al., 1976 and Bartsch
is higher than in age-matched et al., 1977a) also reported no significant
of normal subjects, with a wide change in calculating T in prostatic car-
f values for each group. A promi- cinoma, but both of these investigative
crease was also seen in the ratio groups estimated T without any purifica-
in patients with prostatic cancer. tion to exclude interference from DHT.
rameter was found to be a more We have found no significant change in
index in assessing androgen serum DHT in patients with carcinoma of
in these patients than T levels the prostate compared to normal subjects,
in contrast to our T data. The level of
.e present study unconjugated T DHT in our patients was 2-0610.20nM,
'T (i.e. the free and protein-bound which is of the same order of magnitude
s) were measured. Most of the reported by others (Habib et al., 1976:
ing T and DHT are bound to pro- 2-4±0-5nM). Bartsch et al. (1977a) initially
'he binding capacity of sex-hor- reported a decrease in serum DHT levels
nding globulin (SHBG) has been in patients with carcinoma compared to
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their conitrol group from orthopaedic and
dermatological clinics. However, this
difference was not maintained in further
studies by the same group of investigators
(Bartsch et al., 1977b).
The importance of the measurement of
DHT lies in its relationship to T, as the
ratio of these two steroids could provide a
more reliable criterion for the assessment
of circulating androgens in this disease.
The high level ofT in the circulating blood
and prostatic tissues of patients with
carcinoma of the prostate suggests that,
unlike in BPH, T may play an important
role in the development of prostatic
carcinoma. The increased T in these
patients may be derived either from the
overproduction of this steroid by the
testis or by a more active conversion of
androstenedione to T by the adrenal.
Although the mean testosterone in
patients with carcinoma of the prostate is
higher than in normal controls, the scat-
tered individual values for this steroid
indicate little practical application in the
diagnosis ofthe prostatic cancer. However,
the combined measurement of T and
DHT provides a more significant criterion
for assessment.
The authors wish to thank the Cancer Research
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